Summary

In a sign that researchers are grappling with therapy development, the 4th International Conference on Clinical Trials on Alzheimer's Disease was filled beyond the capacity of its venue, drawing 522 researchers from around the globe. Held 3-5 November 2011 in San Diego, CTAD is the brainchild of Paul Aisen, Jacques Touchon, Bruno Vellas, and Michael Weiner.

The conference posted no ringing trial successes; instead, scientists worked on methodological aspects they hope will improve future trials’ chances. Setting the stage for this work was Paul Aisen’s keynote address spanning a historical arc of when and how therapeutic trials in AD started, how they got stuck in the current trough of negative results, and how he believes they might move forward again. Alzforum asked Aisen to give his lecture a second time on our Webinar platform to share it with the wider global research community. For more background, see ARF related conference story. The Webinar recording below anchored Alzforum’s CTAD 2011 coverage. Play the recording, and share your questions and comments about it in the comment box below.

  • Paul Aisen's Opening Lecture

Background

Comments

Make a Comment

To make a comment you must login or register.

Comments on this content

No Available Comments

References

News Citations

  1. Whence and Where To: History and Future of AD Therapy Trials

Further Reading

Papers

  1. . Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science. 2000 Aug 11;289(5481):957-60. PubMed.

News

  1. Whence and Where To: History and Future of AD Therapy Trials
  2. Nutrient Formulation Appears to Grease Memory Function
  3. Door Slams on RAGE